ACE-031: Exploring Potential Research Lines


ACE 031 is a dissolvable activin receptor type IIB (ActRIIB) protein, a biological agent, and IgG1-Fc. Studies suggest the ACE-031 peptide may control muscle size in mice by blocking the natural production of myostatin, a protein secreted in the muscles that act as a growth factor, and other ligands that restrict muscle development.

ACE 031 Peptide: What is it?

The recombinant fusion protein this peptide may contain was created by joining two parts of a mouse’s immune system—the ActRIIB receptor and the antibody. By decreasing the off signal, which stops muscle synthesis, the muscles become more resilient. Studies have purported that ACE-031 may inhibit the secretion of these ligands, leading to enhanced muscle growth.

In various animal studies, ACE-031 has appeared to exhibit the potential to considerably promote muscular hypertrophy and muscle strength. Additionally, it has indicated efficacy in warding against neuromuscular diseases and muscle atrophy.

ACE-031 Peptide and Muscle

Acceleron CEO John Knopf, Ph., suggested that ACE-031 may have “great potential” as an adjuvant for neuromuscular illnesses in mice. These diseases include muscular dystrophy and amyotrophic lateral sclerosis (ALS).

In disorders like amyotrophic lateral sclerosis and muscular dystrophy, muscle mass degeneration is the direct cause of mortality in mice, highlighting the importance of muscle to their overall health. Researchers are increasingly learning more and more about the potential role ACE-031 may play in preventing muscle atrophy.

Animals suffering from renal failure and cancer cachexia have suggested lessening of muscle and strength loss when given myostatin-blocking substances such as ACE 031. They have also been hypothesized to stimulate insulin sensitivity, inflammation reduction, fat mass loss, bone repair, and mineralization, among other properties. No matter the expression of fiber types, ACE-031 seems to enhance muscle hypertrophy in mouse research.

ACE-031 Peptide and Neuromuscular Activity

The results of the Phase 1 single-concentration clinical trial for ACE-031 purported that the peptide might increase lean body mass; this was announced by Acceleron Pharma, Inc., a biopharmaceutical company that develops novel adjuvants to promote the growth of cells and tissues, including muscle, red blood cells, and bone.

The Chief Medical Officer of Acceleron, Matthew Shermice, M.D., expressed his satisfaction with the positive data and biological effects speculated in the ACE-031 Phase 1 clinical trial. “After only one substance presentation, these effects were observed in muscle, bone, and fat. Lean body mass, muscle volume, bone formation, and biomarkers for fat mass were all quickly, steadily, and concentration-dependently raised by ACE-031. Given these findings, we are excited to continue developing ACE-031 to manage neuromuscular disorders in mice and have started Phase 1 multiple-concentration research.”

ACE-031 Peptide Properties

A soluble variant of the activin receptor type IIB (ActRIIB), ACE-031, has been expertly produced to provide scientists with a potent tool for investigating the function of the activin/myostatin pathway in muscle development and growth. Compared to other research tools, this peptide may have many properties, such as a high affinity for activin and myostatin, a strong inhibitory impact on these growth factors, and the possibility of using it to investigate illnesses related to muscle wasting and other disorders.

ACE-031 Peptide and Disease

There is encouraging data suggesting that ACE-031 may be a helpful adjuvant in the context of illnesses characterized by muscular atrophy and wasting in animal models. Research in animal models, including monkeys and mice, has suggested that ACE-031 may successfully inhibit muscle atrophy and increase muscular development. Scientists hypothesize that ACE-031, which may block myostatin and activin, might provide important information on the causes of these diseases and may lead to the identification of novel research targets.

ACE-031 Peptide in Molecular and Cellular Biology

Researchers may learn more about how myostatin and activin regulate muscle mass and strength by exploring ACE-031, which has been speculated to inhibit their effect. This insight may have the potential to lead to better mitigating avenues for disorders affecting the muscles and general dysfunction in a wide range of animal species.

ACE-031 Peptide

Fusing the extracellular domain of ActRIIB with an immunoglobulin Fc domain is the process theorized to be used to create and alter ACE-031. Research suggests that a persistent and soluble receptor type that may bind and neutralize myostatin and activin is produced by this fusion. Thanks to recent developments in peptide synthesis and protein engineering, ACE-031 is considered a potentially effective tool for investigating the activin/myostatin pathway thanks to its proposed stability, affinity, and potency.

ACE-031 Peptide: Future Research Lines

There are several interesting avenues to pursue as ACE-031 research develops. These include finding the best technique to present ACE-031 to different animal models, studying its effects on different muscle tissue, and discovering if it synergizes with other growth factors or signaling pathways. This study’s findings may pave the way for new ways of thinking about muscle biology and managing disorders that cause muscle atrophy.

Buy ACE-031 if you are a researcher interested in further studying this compound. Please note that none of the substances mentioned in this article have been approved for human consumption. 


  • [i] “Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys With Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial,” Craig Campbel, Hugh J McMillan, Jean K Mah, Mark Tarnopolsky, Kathryn Selby, Ty McClure, Dawn M Wilson, Matthew L Shermice, Diana Escolar, Kenneth M Attie
  • [ii] “Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial,”
  • [iii] Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607.
  • [iv] Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804.
  • [v] Silva GC, Braga FC, Lima MP, Pesquero JL, Lemos VS, Cortes SF. Hancornia speciosa Gomes induces hypotensive effect through inhibition of ACE and increase on NO. J Ethnopharmacol. 2011 Sep 1;137(1):709-13. doi: 10.1016/j.jep.2011.06.031. Epub 2011 Jul 3. PMID: 21756990.